HTLV-1 is the etiologic agent of ATL and HAM/ TSP. The majority of HTLV-1-infected individuals remain asymptomatic, indicating that the infection alone is not sufficient to cause the diseases. It has been reported that cytokine gene polymorphisms, including polymorphisms at IL-6 and IL-10 gene, might be important. We analyzed SNP in the promoter region of the IL-6: À174, À572, À597, and À634 positions, and IL-10: À592 position to evaluate the role of these polymorphisms in the HAM/TSP pathogenesis in 133 HTLV-1 infected individuals and in 100 healthy individuals from Salvador, Bahia, Brazil. The À634C allele frequencies were higher among HAM/TSP patients (21.2%) than among oligosymptomatic (6.5%; P ¼ 0.038) and asymptomatic (9.5%; P ¼ 0.025) subjects. Similarly, the À174G allele frequencies were higher in HAM/ TSP patients than in oligosymptomatic patients (P ¼ 0.02). Moreover, the À634GC/À174GG genotype combination was identified at a higher frequency (38.5%) in the HAM/TSP patients than in subjects with other clinical status (8.7%; P ¼ 0.016 for oligosymptomatic and 15.5%, P ¼ 0.012 for asymptomatic patients). However, the multivariate logistic regression including the genotypes of the three studied loci showed that only À634 C IL-6 carriers remain as significant and independent TSP/HAM predictor (odds ratio [OR] ¼ 5.31; 95% [CI] ¼ 1.60-17.56; P ¼ 0.006). We suggest that À634 G C in IL-6 could contribute to HAM/TSP development and that identification of the collective influence of several cytokine polymorphisms, their prevalence, and their interaction could help to better understand this disease.
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INTRODUCTION
The human T-cell lymphotropic virus type 1 (HTLV-1) (Family Retroviridae, subfamily Orthovirinae, genus Deltaretrovirus, species Primate T-lymphotropic virus I) is the etiologic agent of adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-1-associated mielopathy (HAM/TSP) [Poiesz et al., 1980; Gessain et al., 1985; Osame et al., 1986] . The majority of HTLV-1-infected individuals remain asymptomatic (95-98%), indicating that the infection alone is not sufficient to cause the diseases [Murphy et al., 1989; Orland et al., 2003] . It has been demonstrated that the Tax protein of HTLV is a transcriptional activator of viral and host cellular genes, including interleukin 2 (IL-2), the a chain of the IL-2 receptor (IL-2Ra), interleukin 6 (IL-6), interleukin 10 (IL-10), c-fos, granulocyte-macrophage colony stimulating factor, etc [Mori et al., 1996; Li and Gaynor, 2000] . Tax does not bind to DNA directly nor has an enzymatic function; its ability to activate many genes is conferred by its protein-protein interactions with different cellular factors [Li and Gaynor, 2000] .
Although few studies have been carried out on the host genetic susceptibility to HAM/TSP [Jeffery et al., 1999; Kodama et al., 2004; Rafatpanah et al., 2004; Saito et al., 2005; Nobuhara et al., 2006] , it has been reported that cytokine gene polymorphisms might play a role in the pathogenesis of this disease [Nishimura et al., 2000; Nishimura et al., 2002; Sabouri et al., 2004] .
Indeed, previous studies have demonstrated that polymorphism at IL-6 and IL-10 promoter, at position À634 and À592, respectively, could be involved in the pathogenesis of HAM/TSP [Nishimura et al., 2002; Sabouri et al., 2004] . However, single nucleotide polymorphisms (SNP) and haplotype frequencies, including that at IL-6 and IL-10 promoter, can differ in populations with different ethnic backgrounds [Fishman et al., 1998; Cox et al., 2001; Hoffmann et al., 2002; Meenagh et al., 2002; Plothow et al., 2003] . Recently, we have demonstrated that there is a great heterogeneity in the frequency of À174G/C and À634G/C IL-6 variants among Brazilian regional subpopulations with different ethnic backgrounds [Gadelha et al., 2005] .
IL-6, a pleiotropic cytokine, is synthesized in response to diverse stimuli and SNP in the human IL-6 promoter at À634, À174 and À572 positions have been associated to the gene function and disease susceptibility [Fishman et al., 1998; Kitamura et al., 2002; Nishimura et al., 2002; Belluco et al., 2003; Kubaszek et al., 2003] . The À174G/C IL-6 variant lies immediately upstream of multi-responsive element (MRE). Compared to the À174G allele, the À174C allele resulted in lower plasma IL-6 levels [Fishman et al., 1998 ].
IL-10 is produced particularly by T regulatory cells, but also by Th 0 , Th 1 , Th 2 , B-cells and monocytes [Moore et al., 2001; Taylor et al., 2006] . This cytokine is related to antigen-specific T-cell suppression (both Th 1 and Th 2 ). The polymorphism at À592 position lies between the Sp1 and Ets recognition site and may affect the binding of the transcriptional factor. In fact, the region between À652 and À571 nucleotide is necessary for IL-10 transcription [Ma et al., 2001 ]. In addition, it has been demonstrated that À592A allele was correlated with in vitro reduced IL-10 production [Rosenwasser and Borish, 1997] and lower HTLV-1 Tax-mediated transcriptional activity .
In this study, we analyzed SNP in the promoter region of the IL-6: À174, À572, À597, and À634 positions, and IL-10: À592 position, in order to evaluate the role of these polymorphisms in the HAM/TSP pathogenesis in samples from Salvador, Bahia, the city with the highest prevalence of HTLV-1 infection in Brazil [Galvã o-Castro et al., 1997; Dourado et al., 2003] .
MATERIALS AND METHODS

Study Design and Population
Hundred thirty-three infected individuals (84 HTLV-1 asymptomatic carriers, 23 oligosymptomatic, and 26 HAM/TSP patients) recruited from the HTLV reference center located at Bahia School of Medicine and Public Health/Bahia Foundation for Scientific Development (EBMSP) between June 2005 and July 2006, and 100 healthy individuals from the general population of Salvador, Bahia, Brazil [Dourado et al., 2003] were enrolled in this study. The HTLV-1 infection in healthy and infected individuals was assessed according to the algorithm recommended by the Brazilian ministry of health. Briefly, plasma samples repeatedly positive in duplicate by ELISA (HTLV-1/ HTLV-2 Ab-Capture ELISA Test System, Ortho, Clinical Diagnostic Inc., Raritan, NJ) were confirmed and discriminated between HTLV-1 and HTLV-2 using Western blot (HTLV blot 2.4, Genelabs, Singapore). The HAM/TSP patients were classified according to the expanded disability status scale (EDSS) and Osames motor disability score (OMDS). All subjects provided written informed consent. The infected individuals classified as oligosymptomatic were clinically different from HAM/TSP patients. They presented some neurological symptoms, such as disabilities in gait and sphincter control areas, weakness, bladder, and erectile dysfunctions, but they did not fulfill the HAM/TSP criteria. All volunteers gave written informed consent before participating. The study received official institutional and ethical approval of the EBMSP/FBDC ethic committee.
DNA Extraction and Single Nucleotide Polymorphism (SNP) Detection
Genomic DNA was previously extracted from peripheral blood mononuclear cells by proteinase K treatment followed by phenol-chloroform method. The analysis of the polymorphisms À634G/C at IL-6 and À592C/A at IL-10 were done by PCR amplification followed by restriction fragment length polymorphism (RFLP) using primers and PCR conditions, as previously described [Nishimura et al., 2002; Sabouri et al., 2004] . The amplified products were digested with BsrBI (634G/ C) and RsaI (À592C/A) restriction endonucleases, and both digested and undigested samples were electrophoresed on 2% agarose gels followed by Ethidium bromide staining. For determination of À174G/C, À572G/C, and À597G/A IL-6 polymorphisms, the SNP assay by real-time PCR was done. The SNP assays were purchased from Applied Biosystem (Foster City, CA), and they were carried out according to the manufacturer's instructions.
Statistical Methods
Allele frequencies were estimated by gene counting. The agreement of genotype frequencies with HardyWeinberg expectations and the linkage disequilibrium were tested using the Genepop [Raymond and Rousset, 1995] . The heterogeneity of polymorphism frequencies among populations was tested by w 2 test followed by adjusted w 2 residual analysis or with Fisher's exact test using the PEPI package, version 4.0 [Abramson and Gahlinger, 2001] . A P-value < 0.05 was considered statistically significant.
RESULTS
The median age of patients with HAM/TSP was 54.0 years (range, 35-79 years; 65.4% female) that of oligosymptomatic patients was 53 years (range, 37-82; 60.9% female), which was greater than that of asymptomatic patients (38 years; range, 18-64 years; 63.1% female).
The nucleotide at position À572 at IL-6 promoter was non-polymorphic and only two heterozygote genotypes were found at À597 (one HAM/TSP patient and one healthy carrier); therefore subsequent association analysis was not carried out. In fact, previous studies have shown that these polymorphisms are rare in African and African-Amerindian populations (Cancer Genome Anatomy Project/SNP500Cancer Database accessed by http://snp500cancer.nci.nih.gov). Table I show the IL-6 and IL-10 polymorphism frequencies in HTLV-1 infected and non-infected subjects. There was no difference between them for the three polymorphic sites analyzed at IL-6 and IL-10 promoter. Genotype frequencies from the three polymorphic sites (À634G/C, À174G/C IL6, and À592C/A IL-10) did not differ significantly from those expected under the Hardy-Weinberg equilibrium.
The distribution of observed À634G/C, À174G/C IL6, and À592C/A IL-10 allele frequencies among HTLV-1 infected patients according to the clinical status (asymptomatic, oligosymptomatic, and HAM/TSP) are shown in Tables II and III . Genotype frequencies did not differ significantly from those expected under the Hardy-Weinberg equilibrium. In relation to IL-6, there was no significant linkage disequilibrium between À634G/C and À174G/C polymorphisms (w 2 ¼ 0.525; Df ¼ 6; P ¼ 0.998). The À634C allele frequencies were higher among HAM/TSP patients (21.2%) than among oligosymptomatic (6.5%) and asymptomatic (9.5%) patients. Similarly the À174G allele frequencies were higher in HAM/TSP patients than in oligosymptomatic patients (P ¼ 0.02), but the difference between HAM/ TSP and asymptomatic patients was not statistically significant (P ¼ 0.12). The À174G allele, defined as ''high'' cytokine producer, was found in 94.2%, 78.3%, and 86.3% of the HAM/TSP patients, oligosymptomatic, and asymptomatic patients, respectively. As regards IL-10, there was no association between the À592C/A IL-10 polymorphism and disease developing in HTLV-1 infected patients.
The analysis of the two-site IL-6 promoter genotype combination frequencies for the three clinical statuses among HTLV-1 infected subjects demonstrated that the wild genotype combination (À634GG/À174GG) was more common in the three groups. The À634GC/ À174GG genotype combination was at a higher frequency (38.5%) in HAM/TSP patients than in subjects with other clinical status (8.7%; P ¼ 0.016 for oligosymptomatic and 15.5%, P ¼ 0.012 for asymptomatic), suggesting that this combination could be related to the development of HAM/TSP (data not shown). However, only the À634C IL-6 carriers remain as significant and independent TSP/HAM predictor (OR ¼ 5.31; 95% CI ¼ 1.60-17.56%; P ¼ 0.006), as shown by the multivariate logistic regression including the genotypes of the three studied loci (Table IV) .
In addition, the À634GC genotype was related to an increased risk of developing HAM/TSP when this group was compared with asymptomatic patients (odds ratio [OR] ¼ 3.12; 95% confidence interval [CI] ¼ 1.07-8.86; P ¼ 0.021) and oligosymptomatic patients ([OR] ¼ 4.89; 95% CI ¼ 1.01-31.08; P ¼ 0.030). Given these OR we could estimate the prevented fraction (Fp) [Jeffery et al., 1999] for the development of HAM/TSP in HTLV-1 TABLE I. À634G/C and À174G/C IL-6 and À592C/A IL-10 in HTLV-1 Infected Individuals and Healthy Individuals Genotypes Alleles infected subjects that carry the À634GG genotype. We estimated the HAM/TSP prevalence at 1% in HTLV-1 infected population similar to previous studies [Jeffery et al., 1999; Sabouri et al., 2004] . The Fp was 68 AE 18% and 48.5 AE 23% in relation to oligosymptomatic and asymptomatic subjects, respectively. This indicates that the GG genotype prevents $68% of potential cases of HAM/TSP in oligosymptomatic patients and $48.5% in asymptomatic. To detect an [OR] ¼ 3, in a sample of 84 versus 26 patients (asymptomatic vs. HAM/TSP), and considering the lowest genotype frequency as 20%, the power of the study is roughly 50% to Fisher's exact test. In relation to allelic frequency, as we have the double, the power of the study is roughly 83%.
DISCUSSION
In this work we have identified an association between À634C IL-6 variant and HAM/TSP unlike what was related before [Nishimura et al., 2002] . A previous study in Japan showed an association between the À634G IL-6 variant and the development of Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) associated myelopathy [Nishimura et al., 2002] . This conflicting result could be due to ethnic's differences. In fact, few studies have investigated the À634C/G IL-6 gene polymorphism, and all had been carried out in Asian populations. Recently, we demonstrated a lower frequency of the À634C IL-6 allele among individuals from Salvador (a city with a high racial admixture and a main contribution from African ancestry) than that observed previously in Asians [Nishimura et al., 2002; Gadelha et al., 2005] .
Moreover, in this study, the HAM/TSP patients presented the highest À174G allele frequency (94.2%). The high IL-6 production could be involved in inflammatory aspects in HAM/TSP patients. In fact, high IL-6 levels have been demonstrated in several inflammatory diseases including rheumatoid arthritis, systemic lupus erithematosus, ankylosing spondylitis, Crohn's disease, and chronic inflammatory proliferative diseases [reviewed by Gabay et al., 2006; Ishihara and Hirano, 2002] . In addition, it has been demonstrated that the blockage of IL-6 and IL-6 signaling seems to be effective at prevention and treatment in inflammatory disease [reviewed by Gabay et al., 2006; Smolen and Maini, 2006] . IL-6 was also related with CNS injury in patients with the neuroinflammatory disorder transverse myelitis, resulting in demyelinization and axonal injury [Kaplin et al., 2005] . Besides, it was demonstrated, in the experimental autoimmune encephalomyelitis, that no inflammatory cells were observed in the central nervous system of IL-6 deficient mice, reinforcing the role of IL-6 in inflammatory disorders in the CNS [reviewed by Ishihara and Hirano, 2002] . In addition, the À174G/C IL-6 polymorphism has been studied extensively and is associated with many disorders [Fishman et al., 1998; Jahromi et al., 2000; Jenny et al., 2002; Villuendas et al., 2002; Kubaszek et al., 2003; Licastro et al., 2003] . Furthermore, the À174G allele at IL-6 resulted in higher plasma IL-6 levels [Fishman et al., 1998 ]. Unexpectedly, no statistical difference between asymptomatic and HAM/ TSP individuals was found. In fact, the genetic susceptibility must be associated to polymorphisms combination or association.
In addition, the analysis of two-site IL-6 promoter genotype estimated frequencies in combination showed that the combination À634GC/À174GG must be related to susceptibility to HAM/TSP development in our population. However, in the multivariate logistic regression analysis including the three loci, only À634C IL-6 allele carriers remain as a significant predictor of HAM/ TSP (OR: 5.3, IC ¼ 1.6-17.6; P ¼ 0.006), independently from the other two loci, showing that the most important effect should be related to À643 G ! C. Moreover, it was found that the À634 C allele in heterozygosity is related to the disease. As the C allele is not so frequent in our population, it was not possible to observe if the effect related to homozygosity could be higher.
We did not find any association between the À592A allele and the outcome of neurological disease in HTLV-1 patients. Sabouri et al. [2004] have shown that the IL-10 À592A allele produced lower HTLV-1 Taxinduced activity and this allele was associated with lower susceptibility to HAM/TSP in individuals from Kagoshima/Japan. In fact, the genotype frequency of our population is different from that of the population analyzed by Sabouri et al. [2004] and this difference could also explain these results. Analyzing the À592A allele frequency in individuals from Salvador, we verified that the À592A allele frequency is lower in African descendents (data not shown).
HAM/TSP patients have higher proviral load levels than asymptomatic. However, the range of these levels is wide and overlapping and there is a consensus that the proviral load is not sufficient to cause the disease. Furukawa et al. [2003] suggested that the low production of inflammatory cytokines in asymptomatic HTLV-1 carriers might contribute to maintain this status, and although a higher provirus load is relevant for the development of disease, other factors must be important. These individuals' differences might be due in part to polymorphism at cytokines genes. In fact, it has been demonstrated that cytokine gene polymorphisms may affect protein production and lead to ''high'' or ''low'' cytokines production [Rosenwasser and Borish, 1997; Fishman et al., 1998 ]. Besides, these polymorphisms frequencies can differ in populations with different ethnic backgrounds [Cox et al., 2001; Meenagh et al., 2002; Gadelha et al., 2005] .
In summary, our results demonstrated that the G allele at À174 and C allele at À634 could contribute to HAM/TSP development. The multivariate analysis showed that the À634C allele seems to be the most important HAM/TSP predictor. In fact, we do not know if the individuals (oligosymptomatic or asymptomatic) will develop HAM/TSP. The disease is progressive, chronic, and its development is slow. Future fellowships are necessary to answer the question. It is very unlikely that single polymorphisms at cytokine genes explain the disease. However, the identification of the collective influence of several cytokine polymorphisms, their prevalence in the population, and their interaction could help us understanding the pathogenesis mechanisms. 
